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Received February 19, 2015; accepted November 11, 2015AbstractBackground: Honokiol, a derivative extracted from the stem and bark of Magnolia officinalis, has been reported to have anticancer effects in
hepatoma cells. Recently, it was found that honokiol acted as not only a retinoid X receptor (RXR) agonist but also as a peroxisome proliferator-
activated receptor gamma (PPARg) agonist. Additionally, honokiol is capable of activating PPARg/RXR heterodimers synergistically in the
presence of rosiglitazone in 3T3-L1 adipocyte and HLE human hepatoma cells. Furthermore, synthetic PPARg agonist thiazolidinediones
exhibited growth inhibition effects in hepatoma cells through PPARg-dependent and PPARg-independent pathways. However, the combined
effects of treatment with honokiol and PPARg agonist are unclear in hepatoma cells.
Methods: In this study, sulforhodamine B assay, flow cytometry, and Western blot analysis were used to examine the combined effects of
honokiol and PPARg agonist (rosiglitazone) treatment on growth inhibition in SK-Hep1 and Mahlavu hepatoma cells.
Results: Honokiol or rosiglitazone treatment in hepatoma cells induced growth inhibition at high dose by sulforhodamine B assay. Moreover, we
found that combined treatment with honokiol and rosiglitazone showed more effective growth inhibition in hepatoma cells than treatment with
honokiol or rosiglitazone alone. Also, treatment with honokiol and rosiglitazone induced cell cycle arrest in the G0/G1 phase; increased p21; and
decreased cyclin D1, cyclin E1, and Rb expression in SK-Hep1 hepatoma cells.
Conclusion: Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation
of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hepatocellular carcinoma (HCC) is the second leading cause
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1726-4901/Copyright © 2016, the Chinese Medical Association. Published by El
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).surgical resection is the best treatment for HCC, especially for
patients with a tumor 5 cm in diameter. Recurrence and
metastasis are the major causes of increased mortality after
treatments such as transcatheter arterial chemoembolization,
chemotherapy, and radiotherapy.2 Therefore, the development of
new therapeutic agents or strategies for HCC is urgently needed.
Peroxisome proliferator-activated receptor gamma (PPARg)
belongs to the nuclear hormone receptors subfamily, whose
members are ligand-dependent transcriptional factors.3 Most
studies have shown that PPARg agonists present antitumoralsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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(TZDs) serve as PPARg agonists and are used as antidiabetic
drugs including pioglitazone, rosiglitazone, ciglitazone, and tro-
glitazone.5 TZDs induce cell growth inhibition, cell cycle arrest,
or apoptosis of tumor cells. In particular, troglitazonemay induce
cytotoxicity and apoptosis in human hepatoma cells.6Moreover, a
study indicated that treatment of hepatoma cells with troglitazone
led to cell growth arrest, which was associated with the sup-
pression of cyclin D1 expression, and the apoptotic process may
be related to the PI3K/Akt signaling pathway.7 Additionally, the
downregulation ofCOX-2andBcl-2, andupregulation ofBax and
Bak were observed in HepG2 hepatoma cells after troglitazone
treatment.8 A recent study showed that rosiglitazone had an
antimetastatic effect in MHCC97L and BEL-7404 human hepa-
toma cell lines.9 Taken together, it seems that PPARg could be a
potential therapeutic target to fight HCC.10 However, the exact
workingmechanism of TZDs and the role of PPARg activation in
HCC are still unclear and thus worthy of further investigation.
Honokiol is a derivative extracted from the stem and bark of
Magnolia officinalis and is reported to exhibit many pharmaco-
logical effects, such as suppression of oxidative stress via regu-
lating the NF-kB (nuclear factor-kappa B) signaling pathway in
human umbilical vein endothelial cells,11,12 antithrombosis ac-
tivity,13 and anti-inflammatory effects through inhibiting signal
transducer and activator of transcription-3 (STAT3).14,15 More-
over, honokiol induced antiproliferation and apoptosis through
inhibiting the STAT3 signaling pathway by regulating tyrosine
phosphatase SHP-1 in HCC cells.16 Furthermore, honokiol
activated the p38 mitogen-activated protein kinase and the
caspase-3 pathway to induce apoptosis in human hepatoma cell
lines.17 Therefore, honokiol may be a potential therapeutic agent
in cancer treatment.
It was found that honokiol performs as a natural rexinoid
and thus is able to serve as an retinoid X receptor (RXR)
agonist.18,19 Additionally, it has been reported that honokiol is
able to synergistically activate the PPARg/RXR heterodimers
in the presence of rosiglitazone in 3T3-L1 adipocyte and HLE
human hepatoma cells.19 However, the combined effects and
detailed mechanism of treatment with honokiol and PPARg
agonist remain unclear in hepatoma cells. In this study, sul-
forhodamine B assay, flow cytometry, and Western blot anal-
ysis were used to examine the combined effects of honokiol
and PPARg agonist (rosiglitazone) treatment on growth inhi-
bition in SK-Hep1 and Mahlavu human hepatoma cells.
2. Methods2.1. Cell cultureMahlavu and SK-Hep1 human heptoma cell lines were
maintained in Dulbecco's modified Eagle's medium supple-
mented with 10% fetal bovine serum (Hyclone), 1% pen-
icillinestreptomycin amphotericin B solution, 1% L-
glutamate, and 1% nonessential amino acids in a 37C incu-
bator containing 5% CO2. All of the reagents mentioned above
were obtained from Gibco (Gaithersburg, MD, USA) and
Biological Industries (Beit Haemek, Israel).2.2. Drug treatmentCells were seeded on 96-well plates with a density of
4000 cells/well and treated with different doses of honokiol
(0mM, 10mM, 20mM, and 40mM; Sigma-Aldrich, St. Louis,
MO, USA) and/or rosiglitazone (0mM, 10mM, 20mM, 50mM,
and 100mM; Cayman, Ann Arbor, MI, USA) and incubated for
24 hours, 48 hours, and 72 hours. Both honokiol and rosigli-
tazone were dissolved in dimethyl sulfoxide.2.3. Sulforhodamine B assaySulforhodamine B (SRB) assay was used to determine cell
viability. Cells were seeded on 96-well plates with a density of
4000 cells/well. After the cells were treated with drugs and
incubated for 24 hours, 48 hours, and 72 hours, 50% trichloro-
acetic acid was added to thewells immediately and the plate was
incubated at 4C for 1 hour to fix the cells.Afterwashing the cells
with ddH2O four times and air-drying them, 0.057% SRB solu-
tion was added to the wells and then the plate was left at room
temperature for 30 minutes away from light. Unincorporated
SRB was washed away with 1% acetic acid four times, and the
platewas left to air-dry. Finally, 10mMTris basewas added to the
wells to solubilize the SRB solution, and the absorbance was
measured at the wavelength of 510 nm. Reagents mentioned
above were purchased from Sigma-Aldrich.2.4. Flow cytometryCells were seeded in six-well plates with a density of
20,000 cells/well. After drug treatment for different time dura-
tions, cells were washed with phosphate buffered saline (PBS;
Gibco) and collected from the six-well plates via treatment with
trypsin EDTA (Biological Industries). The supernatant was dis-
carded after centrifugation (270g, 5 minutes), and the cell pellet
waswashedwith cold PBS and centrifuged again. PBSwas added
to the cell pellet, and then the sample was transferred to a 5-mL
round-bottom tube. The sample was fixed with 70% cold
ethanol and stored at 4C for at least 1 hour. Next, the samplewas
centrifuged and washed with PBS in order to remove the 70%
ethanol. Propidium iodide (PI) solution, composed of 0.1%Triton
X-100, 20 mg/mL PI, and 0.2 mg/mLRNase A, dissolved in PBS,
was added to the samplewithout light. After staining for 1 hour in
the dark, samples were filtered using a 5-mL round-bottom tube
with cell-strainer cap and analyzed by flow cytometry. Afterward,
cell cycle distribution was quantified using Cell-quest software
(Becton Dickinson (San Jose, CA, USA)), and the detailed per-
centage of the cell cycle was analyzed usingModFit LT software
(Verity Software House (Topsham, ME, USA)). Reagents for PI
staining were purchased from Sigma-Aldrich, and the FACSCa-
libur flow cytometer was obtained from Becton Dickinson (San
Jose, CA, USA).2.5. Western blotCellswere resuspendedwithRIPA (radioimmunoprecipitation
assay) buffer [150mM NaCl, 50mM TriseHCl, 0.25% sodium
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(SDS)] supplemented with protease inhibitor cocktail (Calbio-
chem, SanDiego, CA, USA) and incubated for 30minutes on ice.
After centrifugation (13,000g, 10 minutes), the supernatant con-
taining the whole-cell lysate was obtained. Protein concentration
was measured using the BCA (bicinchoninic acid) assay. Protein
lysates were separated in 12% SDS-PAGE (polyacrylamide gel
electrophoresis) in running buffer (25mM Tris pH 8.8, 192mM
glycine, 0.1%SDS). The separated proteinswere transferred onto
a polyvinylidene difluoride membrane in transfer buffer (25mM
Tris pH 8.8, 192mM glycine, 20% methonal). After blocking the
membrane in TBST buffer (Tris-buffered saline, 0.1% Tween 20)
with 5%milk at room temperature for 1 hour, primary antibodies
(p21, cyclin D1, cyclin E1, and Rb) were used to probe the pro-
teins on the membrane at 4C overnight. After incubation with
horseradish peroxidase-conjugated secondary antibody, the pro-
bed proteins were detected by an enhanced chemiluminescence
system (Thermo, Waltham, MA, USA).2.6. Statistical analysisThe means and standard deviation were calculated from
three independent experiments. Student t test was used for
comparing the means of the two treatment groups. Differences
were considered statistically significant at p < 0.05.
3. Results3.1. Honokiol and/or rosiglitazone induced growth
inhibition in hepatoma cell linesThe SRB assay was used to examine the cytotoxic effects
of honokiol and/or rosiglitazone treatment in SK-Hep1 and
Mahlavu hepatoma cell lines. Different doses of honokiol
(0mM, 10mM, 20mM, and 40mM) and rosiglitazone (0mM,
10mM, 20mM, 50mM, and 100mM) were used to treat hepa-
toma cells for 24 hours, 48 hours, and 72 hours. Treatment of
SK-Hep1 and Mahlavu cells with honokiol (40mM) for
48 hours led to growth inhibition (Figs. 1A and 1D). For the
effects of rosiglitazone, SK-Hep1 cells showed growth inhi-
bition when treated by rosiglitazone (50mM) for 72 hours,
whereas there was no significant effect in Mahlavu cells under
this treatment (Figs. 1B and 1E). Also, it is observed that
combined treatment with honokiol (20mM) and rosiglitazone
(50mM and 100mM) induced growth inhibition in SK-Hep1
hepatoma cells but not in Mahlavu cells (Figs. 1C and 1F).3.2. Honokiol and/or rosiglitazone treatment resulted in
cell cycle arrest in hepatoma cell linesAfter examining the growth inhibition caused by honokiol
and/or rosiglitazone treatment in SK-Hep1 and Mahlavu cells,
we further investigated whether these treatments would have
any impact on the cell cycle distribution of hepatoma cells.
Analysis with flow cytometry revealed that treatment with
honokiol (40mM) for 48 hours or 72 hours induced a G0/G1
phase arrest in SK-Hep1 cells (Fig. 2A). We also foundincreased percentage of the G0/G1 phase in SK-Hep1 hepa-
toma cells after treatment with honokiol (20mM) and rosigli-
tazone (50mM and 100mM) for 48 hours (Fig. 2B). The cell
cycle distribution is shown in Figs. 2C and 2D. Moreover, it
was found that cotreatment with honokiol and rosiglitazone in
SK-Hep1 cells for 24 hours did not increase the percentage of
the G0/G1 phase, which was consistent with the results of the
SRB assay (data not shown).3.3. Expression of cell cycle-related proteins after
honokiol and/or rosiglitazone treatment in SK-Hep1
hepatoma cellsAfter examining the effects of honokiol and/or rosiglita-
zone treatment on cell cycle distribution of SK-Hep1 hepa-
toma cells, we found that these treatments increased the
percentage of the G0/G1 phase. We further investigated the
expression of G0/G1 phase-related proteins under these drug
treatments. We found increased p21 and decreased cyclin D1,
cyclin E1, and Rb levels after treatment with 40mM honokiol
for 24 hours. The same phenomena were observed at 48 hours
except for the expression of cyclin E1 (Fig. 3A). In addition,
combined treatment with honokiol (20mM) and rosiglitazone
(50mM and 100mM) for 24 hours and 48 hours were observed
with the same results. However, the expression of Rb was
increased after rosiglitazone treatment for both 24 hours and
48 hours. For the combined treatment groups, the expression
of Rb was decreased at 24 hours but increased at 48 hours
(Fig. 3B). Our results indicated that honokiol combined with
rosiglitazone had a more effective impact on growth inhibition
in SK-Hep1 hepatoma cells by regulating the expression of
cyclin D1, cyclin E1, Rb, and p21.
4. Discussion
In this study, we focused on the interaction between hono-
kiol and PPARg activation and further investigated the com-
bined effects of honokiol and PPARg agonist (rosiglitazone) on
antiproliferative effects in human hepatoma cell lines. In our
observation, honokiol or rosiglitazone treatment on SK-Hep1
(Figs. 1Ae1C) and Mahlavu (Figs. 1De1F) cells exhibited
growth inhibition effects under certain conditions. The results
showed that honokiol reduced the cell viability in a dose- and
time-dependent manner in human hepatoma cells (Figs. 1A and
1D), which was consistent with previous studies.16,17 However,
the growth of rosiglitazone-treated Mahlavu cells did not show
significant changes even when the concentration reached up to
100mM (Fig. 1E). A previous study showed that the cell
viability of human heptoma cells (BEL-7402 and Huh7) was
decreased after treatment with 30mM rosiglitazone.20 Different
responses induced by the same drug may result from the
different characteristics of the cell lines. These results showed
that SK-Hep1 cells are more sensitive to honokiol or rosigli-
tazone than are Mahlavu cells. Additionally, a low dose of
honokiol (20mM) combined with the higher doses of rosigli-
tazone (50mM or 100mM) showed more efficient growth inhi-
bition in SK-Hep1 cells compared to either drug alone.
Fig. 1. Effects of honokiol (HN) and/or rosiglitazone (R) treatment on cell growth in SK-Hep1 and Mahlavu hepatoma cells. SRB assay was used to measure the
growth of hepatoma cells after treatment with (A, D) HN (0mM, 10mM, 20mM, 40mM), (B, E) R (0mM, 20mM, 50mM, 100mM), (C, F) HN (0mM, 20mM) and/or R
(0mM, 50mM, 100mM) for 24 hours, 48 hours, and 72 hours in (AeC) SK-Hep1, and (DeF) Mahlavu hepatoma cells, respectively. Data are expressed as
mean ± standard deviation (SD) from three independent experiments. *p < 0.05; **p < 0.01, significantly different compared to respective control group.
SRB ¼ sulforhodamine B.
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cated that honokiol (40mM) treatment in SK-Hep1 cells
resulted in G0/G1 arrest (Fig. 2A). However, our results are
different from those of a previous study that indicated that
honokiol (50mM) induced the accumulation of the sub-G0
phase in HepG2 hepatoma cells.16 The difference may result
from the differentiation status of hepatoma cell lines because
HepG2 are well differentiated and SK-Hep1 are poorly
differentiated hepatoma cells.21 Honokiol treatment in well-
differentiated hepatoma cells may show more effective anti-
tumor effects. Also, when we examined the combined effects
of honokiol and rosiglitazone on growth inhibition in SK-
Hep1 cells, we observed that the percentage of the G0/G1
phase was enhanced in SK-Hep1 cells after the combined
treatment of honokiol and rosiglitazone for 48 hours (Fig. 2B).
These results together indicated that honokiol potentiated the
growth inhibition effect via regulating cell progression.Previous studies showed that honokiol and PPARg agonists
induced cell cycle arrest and upregulated cell cycle arrest-
related proteins expressions.22,23 Because we had also found
G0/G1 phase arrest after drug treatment (Fig. 2A), we further
examined the expression of G0/G1 phase-related proteins after
drug treatments in SK-Hep1 cells. We observed that p21 was
upregulated and cyclin D1, cyclin E1, and Rb were down-
regulated after honokiol treatment for 24 hours or 48 hours
and thus increased the percentage of the G0/G1 phase in SK-
Hep1 hepatoma cells (Fig. 3A). In addition, we found that
combined treatment with honokiol and rosiglitazone induced
more effective growth inhibition in SK-Hep1 hepatoma cells
mediated through regulating the expression of p21, cyclin D1,
cyclin E1, and Rb and cell cycle progression (Fig. 3B). Our
results are consistent with those of recent studies, which re-
ported that honokiol induced growth inhibition by down-
regulating the expression of cyclin D1 in HepG2 cells.16
Fig. 2. Effects of honokiol (HN) and/or rosiglitazone (R) treatment on cell cycle phase distribution in SK-Hep1 hepatoma cells. Flow cytometry was used to
analyze the distribution of cell cycle phases in SK-Hep1 hepatoma cells after drug treatments. (A) The representative cell cycle profile of SK-Hep1 cells after
treatment with HN (0mM, 40mM) for 48 hours and 72 hours, respectively. (B) Representative cell cycle profile of SK-Hep1 cells after HN (0mM, 20mM) and/or R
(0mM, 50mM, 100mM) treatment for 48 hours. (C, D) Stacked bar graphs were the quantification results for panels A and B. Data are expressed as mean ± standard
deviation (SD) from three independent experiments. *p < 0.05; **p < 0.01, significantly different compared to respective control group.
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observed in MiaPaCa and Panc1 pancreatic cancer cells after
honokiol treatment.24 In another recent study, it was claimed
that honokiol synergistically potentiated the activation of
PPARg/RXR heterodimers in the combination of rosiglitazone
in 3T3-L1 adipocytes and HLE human hepatoma cells to in-
crease glucose uptake.19 Importantly, our study demonstratesthat treatment with honokiol and PPARg agonist had syner-
gistic effects on growth inhibition in SK-Hep1 cells. More-
over, our pilot study has found that the expression of PPARg
and RXRa was decreased after treatment with honokiol and/or
rosiglitazone at 24 hours and 48 hours (data not shown). This
finding was consistent with results in previous studies in lung
cancer cells and gastric cancer cells.25,26
Fig. 3. Effect of honokiol (HN) and/or rosiglitazone (R) treatment on cell cycle-related proteins in SK-Hep1 hepatoma cells. Western blot analysis was used to
detect the expression of cyclin D1, cyclin E1, Rb, and p21 after (A) HN treatment (0mM, 20mM, 40mM) and (B) HN (0mM, 20mM) and/or rosiglitazone (0mM,
50mM, 100mM) treatment for 24 hours and 48 hours in SK-Hep1 hepatoma cells. a-Tubulin was used as loading control.
420 H.-C. Chen et al. / Journal of the Chinese Medical Association 79 (2016) 415e421In conclusion, we have shown the effects of honokiol and/
or rosiglitazone on growth inhibition in human hepatoma cells.
We found that combined treatment with honokiol and rosi-
glitazone induced more effective growth inhibition than
treatment with honokiol alone in SK-Hep1 cells. We suggest
that the growth inhibition is mediated through regulating the
expression of G0/G1 phase-related proteins and may be
involved in the PPARg-related signaling pathway.
Acknowledgments
This work was supported by grants NSC 102-2320-B-075-
003 and V102C-096 from the National Science Council and
Taipei Veterans General Hospital, Taiwan, respectively.
References
1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:
1118e27.
2. Tang ZY. Hepatocellular carcinomadcause, treatment and metastasis.
World J Gastroenterol 2001;7:445e54.
3. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nu-
clear control of metabolism. Endocr Rev 1999;20:649e88.4. Borbath I, Horsmans Y. The role of PPARgamma in hepatocellular car-
cinoma. PPAR Res 2008. http://dx.doi.org/10.1155/2008/209520.
5. Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer
agents. Cancer Ther 2008;6:25e34.
6. Yamamoto Y, Nakajima M, Yamazaki H, Yokoi T. Cytotoxicity and
apoptosis produced by troglitazone in human hepatoma cells. Life Sci
2001;70:471e82.
7. Mishra P, Paramasivam SK, Thylur RP, Rana A, Rana B. Peroxisome
proliferator-activated receptor gamma ligand-mediated apoptosis of he-
patocellular carcinoma cells depends upon modulation of PI3Kinase
pathway independent of Akt. J Mol Signal 2010;5:20.
8. Li MY, Deng H, Zhao JM, Dai D, Tan XY. PPARgamma pathway acti-
vation results in apoptosis and COX-2 inhibition in HepG2 cells. World J
Gastroenterol 2003;9:1220e6.
9. Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, et al. PPARgamma
inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J
Cancer 2012;106:1486e94.
10. Wu CW, Farrell GC, Yu J. Functional role of peroxisome-proliferator-
activated receptor gamma in hepatocellular carcinoma. J Gastroenterol
Hepatol 2012;27:1665e9.
11. Sheu ML, Chiang CK, Tsai KS, Ho FM, Weng TI, Wu HY, et al. Inhi-
bition of NADPH oxidase-related oxidative stress-triggered signaling by
honokiol suppresses high glucose-induced human endothelial cell
apoptosis. Free Radic Biol Med 2008;44:2043e50.
12. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB. Hon-
okiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits
421H.-C. Chen et al. / Journal of the Chinese Medical Association 79 (2016) 415e421invasion through modulation of nuclear factor-kappaB activation pathway.
Mol Cancer Res 2006;4:621e33.
13. Hu H, Zhang XX, Wang YY, Chen SZ. Honokiol inhibits arterial
thrombosis through endothelial cell protection and stimulation of prosta-
cyclin. Acta Pharmacol Sin 2005;26:1063e8.
14. Munroe ME, Arbiser JL, Bishop GA. Honokiol, a natural plant product,
inhibits inflammatory signals and alleviates inflammatory arthritis.
J Immunol 2007;179:753e63.
15. Yu C, Zhang Q, Zhang HY, Zhang X, Huo X, Cheng E, et al. Targeting the
intrinsic inflammatory pathway: honokiol exerts proapoptotic effects
through STAT3 inhibition in transformed Barrett's cells. Am J Physiol
Gastrointest Liver Physiol 2012;303:G561e9.
16. Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, et al.
Honokiol inhibits signal transducer and activator of transcription-3
signaling, proliferation, and survival of hepatocellular carcinoma cells via
the protein tyrosine phosphatase SHP-1. J Cell Physiol 2012;227:2184e95.
17. Deng J, Qian Y, Geng L, Chen J, Wang X, Xie H, et al. Involvement of p38
mitogen-activated protein kinase pathway in honokiol-induced apoptosis in
a human hepatoma cell line (hepG2). Liver Int 2008;28:1458e64.
18. Kotani H, Tanabe H, Mizukami H, Makishima M, Inoue M. Identification
of a naturally occurring rexinoid, honokiol, that activates the retinoid X
receptor. J Nat Prod 2010;73:1332e6.
19. Kotani H, Tanabe H, Mizukami H, Amagaya S, Inoue M. A naturally
occurring rexinoid, honokiol, can serve as a regulator of various retinoid x
receptor heterodimers. Biol Pharm Bull 2012;35:1e9.
20. Cao LQ, Wang XL, Wang Q, Xue P, Jiao XY, Peng HP, et al. Rosiglita-
zone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracilantitumor activity through activation of the PPARgamma signaling
pathway. Acta Pharmacol Sin 2009;30:1316e22.
21. Liu TZ, Chen PY, Chiu DT, Wei JS, Chang KS, Lin KH. Detection of a
novel lactate dehydrogenase isozyme and an apparent differentiation-
associated shift in isozyme profile in hepatoma cell lines. Cancer Lett
1994;87:193e8.
22. Cheung KF, Zhao J, Hao Y, Li X, Lowe AW, Cheng AS, et al. CITED2 is a
novel direct effector of peroxisome proliferator-activated receptor gamma
in suppressing hepatocellular carcinoma cell growth. Cancer 2013;119:
1217e26.
23. Hahm ER, Singh SV. Honokiol causes G0eG1 phase cell cycle arrest in
human prostate cancer cells in association with suppression of retino-
blastoma protein level/phosphorylation and inhibition of E2F1 transcrip-
tional activity. Mol Cancer Ther 2007;6:2686e95.
24. Arora S, Bhardwaj A, Srivastava SK, Singh S, McClellan S, Wang B, et al.
Honokiol arrests cell cycle, induces apoptosis, and potentiates the cyto-
toxic effect of gemcitabine in human pancreatic cancer cells. PLoS One
2011;6:e21573.
25. Liu SH, Shen CC, Yi YC, Tsai JJ, Wang CC, Chueh JT, et al. Honokiol
inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and
consequent inhibition of peroxisome proliferator-activated receptor-
gamma and COX-2-dependent signals. Br J Pharmacol 2010;160:
1963e72.
26. Liu SH, Lee WJ, Lai DW, Wu SM, Liu CY, Tien HR, et al. Honokiol
confers immunogenicity by dictating calreticulin exposure, activating ER
stress and inhibiting epithelial-to-mesenchymal transition. Mol Oncol
2015;9:834e49.
